{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:20:24Z","timestamp":1767972024706,"version":"3.49.0"},"reference-count":64,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic immune-mediated disease that is linked to an increased risk of cancer. Although numerous studies have explored whether neoplasms are concurrent conditions or are induced by psoriasis, a definitive definition remains elusive. In this study, we conducted a comprehensive narrative literature review to offer practical guidance to oncologists and dermatologists regarding the initiation and discontinuation of biologics for psoriasis. The findings indicate that a customized approach is recommended for each patient, and that a history of malignancies does not constitute an absolute contraindication for biologics. Growing evidence supports the treatment of selected patients, emphasizing a nuanced assessment of benefits and risks. There is a lack of data specifying a safe timeframe to initiate biologics following a neoplasm diagnosis due to influences from cancer-related and patient-specific characteristics impacting prognosis. Some patients may continue anti-psoriasis therapy during cancer treatments. Enhanced comprehension of the biological mechanisms in cancer progression and the immune microenvironment of psoriasis holds promise for refining therapeutic strategies. In conclusion, a personalized treatment approach necessitates collaboration between oncologists and dermatologists, considering factors such as cancer prognosis, psoriasis clinical manifestations, patient characteristics, and preferences when making treatment decisions.<\/jats:p>","DOI":"10.3390\/ijms242417540","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T03:59:24Z","timestamp":1702871964000},"page":"17540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8605-4290","authenticated-orcid":false,"given":"Nerina","family":"Denaro","sequence":"first","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8534-6497","authenticated-orcid":false,"given":"Gianluca","family":"Nazzaro","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Murgia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-9152","authenticated-orcid":false,"given":"Federica","family":"Scarf\u00ec","sequence":"additional","affiliation":[{"name":"UOSD Dermatology, USL Toscana Centro-Prato Hospital, 59100 Prato, Italy"},{"name":"Section of Dermatology, Department of Health Sciences, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Cauchi","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University of Cagliari, 09042 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-5546","authenticated-orcid":false,"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University of Cagliari, 09042 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-5410","authenticated-orcid":false,"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Passoni","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.disamonth.2018.06.001","article-title":"Biologics for the primary care physician: Review and treatment of psoriasis","volume":"65","author":"Schadler","year":"2019","journal-title":"Dis. Mon."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kamiya, K., Kishimoto, M., Sugai, J., Komine, M., and Ohtsuki, M. (2019). Risk Factors for the Development of Psoriasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184347"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000111512","article-title":"Association between psoriasis and the metabolic syndrome. A cross-sectional study","volume":"216","author":"Cohen","year":"2008","journal-title":"Dermatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.it.2005.10.003","article-title":"Understanding the IL-23-IL-17 immune pathway","volume":"27","author":"McKenzie","year":"2006","journal-title":"Trends Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00005-006-0002-6","article-title":"Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27","volume":"54","author":"Beadling","year":"2006","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaad.2016.09.047","article-title":"The risk of melanoma and hematologic cancers in patients with psoriasis","volume":"76","author":"Reddy","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Caputo, V., Strafella, C., Cosio, T., Lanna, C., Campione, E., Novelli, G., Giardina, E., and Cascella, R. (2021). Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 12.","DOI":"10.3390\/genes12091398"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: Should we be paying more attention?","volume":"16","author":"Loft","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and Metabolism in the Tumor Microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.autrev.2018.03.014","article-title":"Pathogenic role of tissue-resident memory T cells in autoimmune diseases","volume":"17","author":"Wu","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2020.2118","article-title":"Association of the Psoriatic Microenvironment With Treatment Response","volume":"156","author":"Wang","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2005.09.025","article-title":"Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity","volume":"25","author":"Bachelez","year":"2005","journal-title":"J. Autoimmun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clindermatol.2007.08.011","article-title":"The cytokine and chemokine network in psoriasis","volume":"25","author":"Nickoloff","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Man, X.-Y., Chen, X.-B., Li, W., Landeck, L., Dou, T.-T., Chen, J.-Q., Zhou, J., Cai, S.-Q., and Zheng, M. (2015). Analysis of epithelial-mesenchymal transition markers in psoriatic epidermal keratinocytes. Open Biol., 5.","DOI":"10.1098\/rsob.150032"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"0300060520919222","DOI":"10.1177\/0300060520919222","article-title":"Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto\u2019s thyroiditis","volume":"48","author":"Zhao","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4110\/in.2020.20.e6","article-title":"IL-17-Producing Cells in Tumor Immunity: Friends or Foes?","volume":"20","author":"Kuen","year":"2020","journal-title":"Immune Netw."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Olsson \u00c5kefeldt, S., Maisse, C., Belot, A., Mazzorana, M., Salvatore, G., Bissay, N., Jurdic, P., Aric\u00f2, M., Rabourdin-Combe, C., and Henter, J.-I. (2013). Chemoresistance of human monocyte-derived dendritic cells is regulated by IL-17A. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056865"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1648","article-title":"New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions","volume":"5","author":"Hunter","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.1003251107","article-title":"IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis","volume":"107","author":"Teng","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yan, J., Smyth, M.J., and Teng, M.W.L. (2018). Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a028530"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5826\/dpc.0904a11","article-title":"Psoriasis in Patients With Active Lung Cancer: Is Apremilast a Safe Option?","volume":"9","author":"Apalla","year":"2019","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_32","first-page":"23","article-title":"Is Apremilast a Safe Option in Patients with History of Melanoma? A Case Series and a Review of the Literature","volume":"15","author":"Gambardella","year":"2022","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1111\/jdv.15671","article-title":"Psoriasis and pregnancy outcomes in biological therapies: A real-life, multi-centre experience","volume":"33","author":"Odorici","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_35","first-page":"S1545961619P0387X","article-title":"Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review","volume":"18","author":"Kahn","year":"2019","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: Should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.4081\/dr.2022.9282","article-title":"Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis","volume":"14","author":"Mastorino","year":"2022","journal-title":"Dermatol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e14889","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/09546634.2021.1886231","article-title":"Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: Long-term safety in a single- center real-life population","volume":"33","author":"Valenti","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/jdv.18329","article-title":"Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: Long-term results from an interim analysis of the SERENA study","volume":"36","author":"Augustin","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: Analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Gupta, A., Peyrin-Biroulet, L., and Ananthakrishnan, A.N. (2023). Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.","DOI":"10.1016\/S0016-5085(23)02504-0"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s13555-023-00966-4","article-title":"Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials","volume":"13","author":"Smith","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1080\/09546634.2021.1942423","article-title":"A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis","volume":"33","author":"Gottlieb","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1007\/s00432-023-05387-6","article-title":"Cancer risks in patients with psoriasis administered biologics therapy: A nationwide population-based study","volume":"149","author":"Jung","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1196966","DOI":"10.3389\/fmed.2023.1196966","article-title":"Brodalumab for the treatment of plaque psoriasis in a real-life setting: A 3\u2009years multicenter retrospective study-IL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1093\/rheumatology\/keaa828","article-title":"Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors\u2014A Nordic cohort study","volume":"60","author":"Hellgren","year":"2021","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Griffiths","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","first-page":"e63","article-title":"Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis","volume":"28","author":"Li","year":"2022","journal-title":"J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1111\/ced.13935","article-title":"Comment on: \u201cTreatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma\u201d","volume":"44","author":"Genovese","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: A study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s10753-015-0165-6","article-title":"Erratum to: Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis","volume":"38","author":"Peled","year":"2015","journal-title":"Inflammation"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, H.-J., and Kim, M. (2023). Challenges and Future Trends in the Treatment of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713313"},{"key":"ref_62","first-page":"169","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J. Immunother. Hagerstown Md 1997"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000491572","article-title":"Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review","volume":"10","author":"Hulstaert","year":"2018","journal-title":"Case Rep. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-023-00905-3","article-title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/24\/17540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:39:54Z","timestamp":1760132394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/24\/17540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":64,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242417540"],"URL":"https:\/\/doi.org\/10.3390\/ijms242417540","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,16]]}}}